Professor of Surgery
Albany Medical College, Albany New York, USA

@BadarMian1

Speech Title: Transperineal and transrectal prostate biopsy: Efficacy and Complications

Appointments:

Professor of Surgery, 1/2019-present
Division of Urology
Albany Medical College, Albany NY

Associate Professor of Surgery, 1/2007- 1/2019
Division of Urology
Albany Medical College, Albany NY

Chief of Urology, 3/2008- 1/2010
Stratton VA Medical Center, Albany, NY

Staff Urologist, 7/2001- 1/2016
Stratton Veterans Affairs Medical Center
Albany, NY

Adjunct Assistant Professor, 7/2002-
Center for Immunology and Microbial Disease
Albany Medical College, Albany NY

Assistant Professor of Surgery, 7/2001- 12/2006
Division of Urology
Albany Medical College, Albany NY

Junior Faculty Associate, 7/2000-6/2001
Dept. of Urology
M. D. Anderson Cancer Center, Houston, TX

Board Certification:

American Board of Urology, 2004, 2014

Education &Training:

Fellowship: Urologic Oncology, M.D. Anderson Cancer Center, Houston, TX. 7/99 – 6/2000

Fellowship: Cancer Biology, M.D. Anderson Cancer Center, Houston, TX.
7/2000 – 8/2001

Chief Resident: Urology, Medical College of Virginia, Richmond, VA.
1/97 – 6/99

Residency: Urology, Medical College of Virginia, Richmond, VA.
7/96 – 12/97

Residency: General Surgery, Medical College of Virginia, Richmond, VA.
7/93-6/96

Medical School: University of the Punjab-Allama Iqbal Medical College, Lahore, Pakistan. 
4/85 – 6/91

Hospital Privileges:

  • Albany Medical Center, Albany, NY
  • Stratton VA Medical Center, Albany, NY

Professional Organizations Membership:

  • American Urological Association
  • Society of Urologic Oncology
  • American Association for Cancer Research
  • Society of University Urologists
  • Northeastern Section, American Urological Association
  • American Association of Clinical Urologists
  • Fellow of American College of Surgeons

Medical Licenses:
          

  • New York    221775-1
  • Texas (inactive)
  • Virginia (inactive)

Honors and Awards:

  • Scholarship Research Award, NS-AUA, 2004.
  • Fellowship Research Award, M.D. Anderson Cancer Center, 2000.
  • Pfizer Scholars in Urology Award, Medical College of Virginia, 1999.

Leadership:

  1. Member-at-large, Board of Directors, Society of Urologic Oncology, 2018-present
  2. Chair, Scientific Program Committee, Northeast-American Urologic Association, 2016
  3. Chair, Membership Committee, Society of Urologic Oncology, 2012-2015
  4. Program Director, Current Concepts in Men’s Health, 2002-2014
  5. Program Director, Annual Summer Conference, Society of Urologic Oncology, 2012
  6. Member, Education Council, American Urological Association, 2011-2012
  7. Leadership Program, American Urological Association, 2010-2011
  8. Member, Board of Directors, American Urological Association-Northeast Section, 2010-2012
  9. Chair, Scholarship Research Committee, American Urological Association, Northeast section 2007-2010

Educational Planning Activities:

  • Scientific Program, Chair, AUA-Northeastern Section, 2016
  • Program Director, Annual Post-Graduate Course, “Current Concepts in Men’s Health”,
    2002-2014
  • Biennial “International Prostate Forum”. Hawaii, Izmir, Kyoto, San Diego, Cypress, Tokyo
    2006-Present

International Hands-On Surgical Workshops:

  1. Sindh Institute of Urology and Transplantation, Robotic Prostatectomy. March 2019
  2. Sindh Institute of Urology and Transplantation, Robotic Prostatectomy, Sep 2018
  3. Sindh Institute of Urology and Transplantation, Robotic Prostatectomy, December 2017
  4. Sindh Institute of Urology and Transplantation, Robotic Pelvic Surgery, August 2017
  5. Jinnah Hospital, Lahore, Laparoscopic Renal Surgery and Uro-oncology, April 2009
  6. Jinnah Hospital, Lahore, Laparoscopic Renal Surgery and Uro-oncology, Feb 2006

Peer Reviewed Journals:

  1. Associate Editor, Urologic Oncology
  2. Associate Editor, BMC Urology      
  3. Section Editor,” Journal Article of the Month”, Urology Times
  4. Reviewer:
    • Journal of Urology
    • Urology
    • British Journal of Urology International

Visiting Professor/Faculty:

  1. Sindh Institute of Urology and Transplantation, Karachi, Pakistan, September 2018
    • “Treatment of Primary Tumor in Metastatic Prostate Cancer”
    • “High Risk Non-Muscle Invasive Bladder Cancer”
  2. Sindh Institute of Urology and Transplantation, Karachi, Pakistan, Dec 21-26, 2017
    • “Anti-androgens: Timing and Sequence”
    • “Use of Androgen Deprivation Therapy in Early Stage Prostate Cancer”,
    • “Immunotherapy in Advanced Prostate Cancer”
  3. Sindh Institute of Urology and Transplantation, Karachi, Pakistan, July 29-31, 2017
    • “Prostate biopsy: Past, Present and Future”,
    • “Bladder Cancer Management After BCG Failure”.
  4. University of the Punjab-A.I. Medical College, Jinnah Hospital, Lahore, Pakistan,
    • “Robotic Surgery for Prostate and Kidney Cancer” April 17-18, 2009
  5. Rensselaer Polytechnic Institute, Physician-Scientist Program, Keynote Speaker,
    • “Use of Robotics in Surgery”. September 27, 2006
  6. Upstate Medical University, Syracuse, NY,
    • “PSA and Cancer Detection in 2006”. September 21, 2006
  7. University of the Punjab-A.I. Medical College, Jinnah Hospital, Lahore, Pakistan,
    • “Localized and Small Renal Masses: Minimally Invasive Options”.  Feb. 12-18, 2006
  8. Siriraj University Hospital, Bangkok, Thailand,
    • “Prostate Biopsy: State of the Art”
    • “Role of Oxidative Stress in Bladder Cancer Metastasis”. May 14-16, 2004

Publications, Peer-reviewed:

  1. Higgins CE, Tang J, Mian BM, Higgins SP, Gifford CC, Conti DJ, Meldrum KK, Samarakoon R, Higgins PJ: TGF-β1-p53 cooperativity regulates a profibrotic genomic program in the kidney: molecular mechanisms and clinical implications. FASEB J. 2019 Jul 6
  2. Higgins SP, Tang Y, Higgins CE, Mian B, Zhang W, Czekay RP, Samarakoon R, Conti DJ, Higgins PJ: TGF-β1/p53 signaling in renal fibrogenesis. Cellular Signaling, 2018 March;43:1-10
  3. Schatz A, Mian BM: Current and emerging trends in prostate cancer immunotherapy. Asian J Androl. 2017 Nov 24
  4. Bharali DJ, Sudha T, Cui H, Mian BM, Mousa SA.: Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer. Nanomedicine. 2017 Jan;13(1):263-273
  5. Ashmalla M, Wang W, Lewis C, Mian BM, Mehsi S: Paraneoplastic leukemoid reaction – poor prognostic marker in urothelial bladder carcinoma. J of Comm and Supp Oncology, Jan 2107
  6. Ross JS, Wang K, Khaira D, Ali SM, Fisher HA, Mian B, Nazeer T, Elvin JA, Palma N, Yelensky R, Lipson D, Miller VA, Stephens PJ, Subbiah V, Pal SK:  Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. Cancer. 2016 Mar 1;122(5):702-11
  7. Akinola S, Ginsburg L, Welliver C, Fisher H, Mian BM, Mechlin C, Kaufman R, McCullough A:  Preoperative PDE5i use is a prognostic metric for poor postoperative erectile function in men undergoing radical prostatectomy: An addition to patient counseling. December 2015, Journal of Clinical Urology 9(6)
  8. Sorokin I, Mian BM: Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection. Asian J Androl. 2015 Jun 23.
  9. Hempel N, Bartling TR, Mian B, Melendez JA: Acquisition of the Metastatic Phenotype is Accompanied by H2O2-Dependent Activation of the p130Cas Signaling Complex. Mol Cancer Res. 2013 Mar;11(3):303-12.
  10. Mian BM. Editorial comment Re:  Routine urine cytology has no role in hematuria investigations. J Urol. 2013 Apr;189(4):1258-9
  11. Dobberfuhl AD, Samarakoon R, Higgins CE, Mian BM, Overstreet JM, Higgins SP, Kogan BA, Higgins PJ: Ureteral Obstruction-Induced Renal Fibrosis: An In Vivo Platform for Mechanistic Discovery and Therapeutic Intervention. Cell Dev Biol. 2012;1(3)
  12. Matsushita K, Ginsburg L, Mian BM, De E, Chughtai BI, Bernstein M, Scardino PT, Eastham JA, Bochner BH, Sandhu JS: Pubovesical fistula: a rare complication after treatment of prostate cancer. Urology. 2012 Aug;80(2):446-51.
  13. Tanner MJ, Welliver RC Jr, Chen M, Shtutman M, Godoy A, Smith G, Mian BM, Buttyan R:  Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells. PLoS One. 2011 Jan 18;6(1):e16027
  14. Mechlin CW, Tanner MJ, Chen M, Buttyan R, Levin RM, Mian BM: Gli-2 Expression and Human Bladder Transitional Cell Invasiveness. J Urol. 2010 Jul;184(1):344-51
  15. Mian BM.  Prostate Cancer Screening and Mortality: Alternative Assessment of Recent Randomized Controlled Clinical Trials. Urologic Oncology, 2010 May-Jun;28(3):233-6
  16. Kalorin CM, Belarmino J, Mian B, De E.: Complete eversion of the urinary bladder: presentation, review, and algorithm for management. Obstet Gynecol. 2009 Feb;113(2 Pt 2):496-501.
  17. Mian BM Editorial Comment. The Journal of urology 1 March 2009 (volume 181 issue 3 Page 1074)
  18. Nazeer T, Kee KH, Ro JY, Jennings TA, Ross J, Mian BM, Shen SS, Suh JH, Lee MJ, Ayala AG.: Intraprostatic adipose tissue: a study of 427 whole mount radical prostatectomy specimens. Hum Pathol. 2009 Apr;40(4):538-41.
  19. Chughtai B, Mian BM.: High risk prostate cancer: evolving definition and approach to management. Can J Urol. 2008 Dec;15(6):4375-80
  20. Bauer R, Kaufman R, Mian BM. Use of anticholinergic therapy in men. Can J Urol. 2008 Dec;15(6):4359-62.
  21. Hempel N, Ye H, Abessi B, Mian B, Melendez JA.: Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic Biol Med. 2009 Jan 1;46(1):42-50
  22. Firoozi F, Nazeer T, Fisher HA, Kaufman RP Jr, White MD, Mian BM.: Tissue-marking scheme for a cost-effective extended prostate biopsy protocol. Urol Oncol. 2009 Jan-Feb;27(1):21-5.
  23. Bratslavsky G, Fisher HA, Kaufman RP Jr, Voskoboynik D, Nazeer T, Mian BM.: PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy. Urol Oncol. 2008 Mar-Apr;26(2):166-70.
  24. Connor KM, Hempel N, Nelson KK, Dabiri G, Gamarra A, Belarmino J, Van De Water L, Mian BM, Melendez JA.: Manganese Superoxide Dismutase enhances the invasive and migratory activity of tumor cells. Cancer Res, 2007 Nov 1;67(21):10260-7.
  25. Buttyan R, Mian BM: Molecularly targeted therapies for renal cell cancer: TRAIL research advances.  J Urol. 2007 May;177(5):1606
  26. Mian BM, Lehr DJ, Moore CK, Fisher HAG, Kaufman, RP, Ross JS, Jennings TA, Nazeer T: Role of Prostate Biopsy Schemes in Accurate Prediction of Gleason Scores. Urology. 2006 Feb;67(2):379-83.
  27. Moore CK, Anwar S, Nazeer T, Fisher HAG, Kaufman RP, Mian BM: Significance of High Grade Prostatic Intraepithelial Neoplasia and Atypical Small Acinar Proliferation in the Contemporary Era. J Urol. 2005 Jan;173(1):70-2
  28. Anwar S, Ambros RA, Jennings TA, Ross JS, Beza A, Mian B, Nazeer T: Expression of cysteine protease protein 32 in prostatic adenocarcinoma correlates with tumor grade. Arch Pathol Lab Med. 2004 Jun;128(6):649-52.
  29. Mian BM: Prostate Biopsy Strategies: Current State of the Art. Journal of National Comprehensive Cancer Network. May 2004;2(3):213-222
  30. Mian BM, Dinney CPN, Bermejo CE, Sweeney P, Tellez C, Bar-Eli M: Fully Human Anti-IL-8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts Via Downregulation of Matrix Metalloproteases and NF-kB. Clin Cancer Res. 2003 Aug; 9(8):3167-3175
  31. Mian BM, Naya Y, Okihara K, Vakar-Lopez, F, Troncoso P, Babaian RJ: Predictors of cancer in repeat extended multi-site prostate biopsy in men with previous negative extended multi-site biopsy. Urology. 2002 Nov; 60(5): 836-40
  32. Huang SF, Kim SJ, Lee AT, Karashima T, Bucana C, Kedar D, Sweeney P, Mian B, Fan D, Shepherd D, Fidler IJ, Dinney CP, Killion JJ: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated Interferon-alpha-2b and Docetaxel. Cancer Res. 2002 Oct 15; 62(20): 5720-6
  33. Sweeney P, Karashima T, Kim SJ, Kedar D, Mian BM, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP: Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res. 2002 Aug;8(8): 2714-24
  34. Huang S, Mills L, Mian BM, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M: Fully humanized neutralizing antibody to IL-8 inhibit angiogenesis, tumor growth and metastasis of human melanoma. Am J Pathol. 2002 Jul; 161(1): 125-34
  35. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johsnton D, Reyes AO, Babaian RJ: Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol 2002; 167: 1675-80
  36. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL: Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol 2002; 167:65-70

Invited Presentations:

  1. “Update on Bladder Cancer”. American Society of Clinical Oncology & SIUT Joint Symposium. Karachi, March 2019
  2. “Update on PSA Screening and How to Manage Prior Negative Biopsy”, 17th International Prostate Forum, Tokyo, October 2018
  3. “Adjuvant versus Salvage Radiotherapy for Recurrent Prostate Cancer”, 17th International Prostate Forum, Tokyo, October 2018
  4. Urovysion FISH Test in the Management of Recurrent Bladder Cancer” 83rd Annual Meeting, Eastern Japanese Urological Association, Tokyo, October 2018
  5. Bladder cancer: Are checkpoint inhibitors the best we can do?”, 8th Annual Research Symposium, Albany College of Pharmacy and Health Sciences, January 2018
  6. “Prostate Biopsy: Past, Present and the Future”, 14th International prostate Forum, Northern Cypress, October 2016
  7. “Hormonal Therapy in Localized Prostate Cancer”, 14th International prostate Forum, Northern Cypress, October 2016
  8. “Anti-Androgens in Metastatic Prostate Cancer”, 14th International prostate Forum, Northern Cypress, October 2016
  9. “Immunotherapy for Prostate Cancer” 14th International prostate Forum, Northern Cypress, October 2016
  10. “Photodynamic Diagnostic Cystoscopy for Bladder Cancer Detection”, Albany NY, July 2016
  11. “How to Manage Positive Urine Cytology”, Annual conference AUA-Northeastern, Quebec City, QC, 2015
  12. “Management of Localized High-Risk Prostate Cancer: Upfront Surgery or Radiation” AUA-Northeastern, Amelia Island, Florida, November 2014
  13. “Risk Calculators, and Updated Tools to Select and Plan a Repeat Prostate Biopsy” 10th International Prostate Forum, Orlando, Florida, May 2014
  14. “Multi-functional nanoparticle-mediated targeting of castration resistant prostate cancer”, 9th International Prostate Forum, Kyoto, Japan, November 2011
  15. “Prostate cancer screening and mortality”, 9th International Prostate Forum, Kyoto, Japan, November 2011
  16. “Translational Research Opportunities in GU Cancers”, 2009 Translational research Symposium: Transforming Basic Science into Clinical Practice, Albany, NY, October 23, 2009
  17. “How and When to Do a Prostate Biopsy?”  9th International Prostate Forum, Izmir, Turkey, October 8-10, 2009
  18. “New Imaging Methods for Prostate Biopsy”, 9th International Prostate Forum, Izmir, Turkey, October 8-10, 2009
  19. “Robotic-Assisted Surgery in Urology”, Annual Meeting of the Pakistan Association of Urologic Surgeons, Lahore, Pakistan, April 2009
  20. “Managing Low-Grade, Small volume Prostate Cancer”, 6th Annual Current Concepts in Men’s Health, Lake George, NY, August 3-5, 2007
  21. “PSA: What is it good for?” 5th  Annual Post-graduate course, Current Concepts in Men’s Health, Lake George, NY, August 11-13, 2006
  22. “BPH, Alpha-Blockers and Floppy Iris Syndrome”, Saratoga Springs, NY. March 29, 2006
  23. Prostate Biopsy: Defining the Optimum Strategy” and “Treating Prostate Cancer–Stage        by Stage, Case Presentations”, Controversies in Prostate Cancer Detection and           Treatment, Kona , Hawaii, March 3-6, 2006
  24. “Emerging Biologic Therapies for Prostate Cancer”, 4th  Annual Post-graduate course, Current Concepts in Men’s Health, Lake George, NY, August 12-14, 2005
  25. “Minimally Invasive Approaches to Kidney Cancer”, Cancer Center, Saratoga Springs, NY. July 28, 2005
  26. “Men’s Health for the Primary Care Provider: Skills You Can Use”, The Desmond Hotel, Albany, New York, February 12, 2005
  27. “High-Risk Prostate Cancer: Multi-Modal Approach”, 3rd Annual Post-graduate course, Current Concepts in Men’s Health, Lake George, NY, August 13-15, 2004
  28. “Improving Prostate Cancer Detection”, Surgical Grand Rounds, Albany Medical College. June 2004
  29. “Clinical Trials and Original Research on Prostate Cancer at Albany Medical College”, Prostate Cancer 101, Inc., Kingston, NY, May 18, 2004
  30. “Medical Management of Lower Urinary Tract Symptoms”, Albany, NY, November 2003
  31. “Prostate Biopsy Schemes: Improving diagnostic and Prognostic Value”, 2nd Annual Post-graduate course, Current Concepts in Men’s Health, Lake George, NY, August 14-17, 2003
  32. “Prostate Cancer: Screening and Early Detection”, Surgical Grand Rounds, Albany Medical College, May 2003
  33. “Prostate Biopsy: A Decade of Evolution”, Post-graduate course, Current Concepts in Men’s Health, Lake George, NY, August 15-17, 2002
  34. “Prostate Cancer”, Albany-Hudson Valley Physician Assistant Program, Albany, NY, July 2002
  35. “Testis Cancer”, Albany-Hudson Valley Physician Assistant Program, Albany, NY, July 2002

Published Abstracts:

  1. Dorff T, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Ali SM, Schrock AB, Fisher H, Mian BM, Tipu Nazeer et al. Comprehensive genomic profiling of urethral cancer to reveal distinctive features compared to bladder cancer. February 2017, Journal of Clinical Oncology 35(6_suppl):429-429
  2. Pal SK, Hoffman-Censits J, Elvin JA, Vergilio J, Suh J, Ramkissoon S, Ali SM, Schrock AB , Fisher H, Mian BM, Tipu Nazeer et al. Comprehensive genomic profiling of relapsed and refractory small cell neuroendocrine carcinoma of the urinary bladder. February 2017, Journal of Clinical Oncology 35(6_suppl):350-350
  3. Ahmad A, Sorokin I, Aggarwal H, Bosukonda A, Mian BM. Controlling the prostate biopsy related infectious complications through vigilant screening and enhanced antibiotic prophylaxis. Apr 2016, The Journal of Urology 195(4):e698-e699
  4. Mahon J, Kaufman R, O’Malley R, Essa, A, Fisher H, Mian BM. Negative predictive value of a negative multi-parametric mri of prostate. April 2016, The Journal of Urology 195(4):e697
  5. Akinola S, Ginsburg L, Fisher H, Mian BM, Kaufman, McCullough A. Use Of Pde-5 Inhibitors (Pde-5i) Before Radical Prostatectomy (Rp) And Nerve Sparing Status (Nss) Predicts Long Term Erectile Failure. April 2012, The Journal of Urology, 187(4):e602
  6. Bharali D, Thangirala S, Yalcin M, Nazeer T, Mousa S, Mian BM. Nanoparticle-Mediated Delivery of Imaging and Therapeutic Agents. April 2012, The Journal of Urology 187(4): e129
  7. Mian BM, Feuerstein M, Fisher H, Kaufman R, Nazeer T. Operator-Dependent Correlation Between Biopsy and Prostatectomy Gleason Score: Potential Impact on Clinical Management. September 2011, Urology 78(3)
  8. Mian BM, Ye H, Hempel N, Melendez A. Superoxide Dependent Differential Regulation of Erk Signaling Controls the Metastatic Potential of Human Bladder Cancer Cells. September 2011, Urology 78(3)
  9. Chen M, Akinola O, Carkner R, Mian BM, Buttyan R.  High-throughput screen for genes that selectively promote growth of androgen independent prostate cancer cells. April 2011, The Journal of Urology 185(4):e164
  10. Welliver C, Tanner M, Chen M, Mian BM, Godoy A, Smith, G, Buttyan. Regulation of prostate stromal cell gene expression by the androgen receptor and its effects on paracrine signaling to prostate cancer cells. April 2011 The Journal of Urology 185(4)
  11. Ye H, Moore E, Hempel N, Melendez A, Mian BM. Mitochondrial superoxide-mediated differential regulation of erk signaling controls the metastatic potential of human bladder cancer cells. April 2011, The Journal of Urology 185(4)
  12. Feuerstein M, Chen M, Tanner M, Mian BM, Buttyan R. Acute androgen deprivation activates notch signaling in prostate cancer cells: evidence of a notch tumor suppressor effect?  April 2011, The Journal of Urology 185(4)
  13. Ye H, Hempel N, Moore E, Mian BM, Melendez A. Differential regulation of Erk signaling by mitochondrial superoxide controls the metastatic potential of bladder cancer cells. January 2011, Cancer Research, 70(8 Supplement):74-74
  14. Ross JS, Yan C, Sheehan GM, Sheehan CE, Nazeer T, Fisher HAG, Mian BM, Kallakury BVS.  Activating transcription factor 3 (ATF3) protein expression in prostatic adenocarcinoma (PAC).  Modern Pathology 23: 215A, 2010.
  15. Nazeer T, Linos KD, Kallakury BVS, HAG Fisher, MIAN BM, CE Sheehan, JS Ross.  Aldehyde dehydrogenase class 1 (ALDH1) expression is associated with disease outcome in prostatic adenocarcinoma (PAC). Modern Pathology 23: 208A, 2010.
  16. Role of Biopsy in the Management Of Small Renal Masses. Bilal Chughtai, Ronald Kaufman, Hugh A.G. Fisher, Gary Sisken, Badar M Mian. The Journal of urology 1 April 2009 (volume 181 issue 4 Page 246)
  17. Evaluation Of Hedgehog Signaling In Human Transitional Carcinoma Cell Lines. Clay W Mechlin, Badar M. Mian, Mathew Tanner, Ralph Buttyan. The Journal of urology 1 April 2009 (volume 181 issue 4 Pages 305-306)
  18. National Patterns Of Diagnosis And Treatment Of Localized Prostate Cancer At Veterans Administration Medical Centers. Ross Bauer, William Conners, Badar M Mian. The Journal of urology 1 April 2009 (volume 181 issue 4 Pages 609-610)
  19. Lu S, Linos K, Ross JS, Jennings TA, Mian B, Sheehan CE, Nazeer T.  Antiproliferative B cell translocation gene 2 protein is downregulated in prostatic adenocarcinoma.  Mod Path 22(180A):815 (abstract); 2009
  20. Linos KD, Lu S, Ross JS, Jennings TA, Mian BM, Nazeer HAT, Sheehan CE, Nazeer T.  Insulin-like growth factor binding protein 3 is upregulated in prostatic adenocarcinoma and correlates with Gleason grade.  Mod Path 22(179A):808 (abstract); 2009
  21. Anonymous Survey To Determine The Management Of Hematuria By VA Primary Care Providers. Carmin M Kalorin, Nazir Memon, Badar M Mian. The Journal of urology 1 April 2009 (volume 181 issue 4 Page 419)
  22. Expression Of Senescence-Associated Growth Regulatory Proteins In Human Prostate Cancer. Badar M Mian, Tipu Nazeer, Eugenia Broude, Igor Roninson. The Journal of Urology 1 April 2009 (volume 181 issue 4 Page 514)
  23. Therapy-Induced Senescence Response And Differential Gene Expression In Prostate Cancer Cells With Variable Metastatic Potential. Badar M Mian, Ross Bauer, Eugenia Broude, Olga Berezovska, Gennady Glinsky, Igor Roninson. The Journal of Urology 1 April 2008 (volume 179 issue 4 Pages 191-192)
  24. The Effect Of Protocadherin-Pc (Pcdh-Pc) Expression On The Invasive Phenotype Of Prostate Cancer Cells. Bilal Chughtai, Elina Levina, Stephane Terry, Francis Vacherot, Alexandre de la Taille, Badar M Mian, Ralph Buttyan. The Journal of urology 1 April 2008 (volume 179 issue 4 Page 425)
  25. Correlation Between Gleason Grade at The Surgical Margin With The Primary Gleason Grade And Biochemical Failure. Michael Feuerstein, Tipu Nazeer, Badar M Mian. The Journal of urology 1 April 2008 (volume 179 issue 4 Page 653)
  26. Oxidative Stress And Regulation Of Invasive Phenotype In Bladder Cancer Cells. James Belarmino, J Andre Melendez, Xio-Fang Ha, Badar M Mian. The Journal of urology 1 April 2008 (volume 179 issue 4 Page 265)
  27. Lu S, Ross JS, Jennings TA, Mian BM, Nazeer HAT, Sheehan CE, Nazeer T. Insulin-like growth factor-1 receptor (IGF-1R) is upregulated in prostatic asdenocarcinoma (PAC) and correlates with Gleason grade. USCAP September 2007
  28. Lu S, Sheehan CE, Jennings TA, Mian BM, Nazeer HAT, Ross JS, Nazeer T. Neural precursor cell-expressed developmentally downregulated 8 (NEDD8) is upregulated in prostatic adenocarcinoma (PAC) and correlates with Gleason grade. USCAP September 2007
  29. Punar M, Ross J, Jennings TA, Mian BM, Nazeer T. Expression of Claudin 1 and Claudin 7 in Prostatic Adenocarcinoma whole mount sections. Mod Pathol,19(1), 156A, 2006.
  30. Nazeer T, Punar M, Ross J, Jennings TA, Mian BM. Intraprostatic Adipose Tissue. Mod Pathol 19(1), 151A, 2006.
  31. Mian BM, Belarmino J, Cho D, Melendez JA: Redox Regulation of Matrix Metalloprotienases in Bladder Cancer: In Vitro Studies. Society of Urologic Oncology, Young Urologic Oncologist Forum, Bethesda, December 2005
  32. James M. Belarmino, Xiao Fang Ha, Andrea Melendez, Badar M. Mian: Role of Superoxide Dismutase in Invasion and Migration in Bladder Cancer. New England and Northeastern section AUA, Bermuda, November 2005
  33. Farzeen Firoozi, Hugh A. G. Fisher, Ronald P. Kaufman, Mark D. White, Tipu Nazeer, Badar M. Mian: A Cost-Effective Protocol In Obtaining Site-Specific Prognostic Information For Extended Prostate Biopsy. New England and Northeastern section AUA, Bermuda, November 2005
  34. Daniel Cho, Xiao Fang Ha, J. Andre Melendez, Louis J Giorgi, Badar M. Mian: Role of Oxidative Stress in Tumorigenic Potential of Bladder Cancer Cells. Annual Meeting, American Urological Association, San Antonio, May 2005
  35. Joel W. Slaton, Steven Schwartz, Neil Wasserman, Badar M Mian: Validation of the Kattan Nomogram for Predicting Cancer on Repeat Prostate Biopsy After an Initial Biopsy Negative for Cancer. Annual Meeting, American Urological Association, San Antonio, May 2005
  36. Punar M, Sheehan CE, Jennings TA, Mian B, Ross JS, Nazeer T. Expression of Smad4 in Prostatic Adenocarcinoma Whole Mount Sections Correlates With Tumor Gleason Grade. Mod Pathol 18(1); 159A, 2005.
  37. Mian B, Agartan C, Levin R, Nazeer T: Bladder Cancer Model in Rabbit Facilitates Endoscopic Diagnosis And Treatment. XXth European Association of Urology Congress-Istanbul, Turkey, March 2005. 
  38. Mian B, Nazeer T:  Impact of Biopsy Scheme On Gleason Score Concordance in Men With Cancer in A Single Biopsy Core. XXth European Association of Urology Congress-Istanbul, Turkey, 2005.
  39. Mian BM, Agartan C, Whitbeck C, Nazeer T, Levin R: A Novel Carcinogenesis Model for Bladder Cancer. Society of Urologic Oncology, Bethesda, December, 2004
  40. Capello SA, Kaufman RP, Jr., Fisher HAG, Mian BM, Tolerability and Efficacy of Bicalutamide Monotherapy in Biochemical Recurrence of Prostate Cancer, The Canadian Journal of Urology: 11(4): 2373, August 2004.
  41. Bratslavsky G, Fisher HAG, Kaufman RP, Jr., Nazeer T, Mian BM. Percent Free Specific Antigen in the Extended Biopsy Era: Still Relevant? The Canadian Journal of Urology:11(4): 2362, August 2004.
  42. Moore CK, Mian B, Fisher H, Kaufman R, Karekehalli S, Nazeer T: Prognostic Value of High Grade Prostatic Intraepithelial and Neoplasia and Atypia in the Extended Prostate Biopsy Era.  The Canadian Journal of Urology; 10(4):1953, August 2003
  43. Mian BM, Anwar S, Nazeer T:  Microfocal Prostate Cancer in One Core Prostate Biopsy: Effect Of Biopsy Schemes in Predicting Potentially Insignificant Cancers. 100th Annual Meeting, American Urological Association, San Francisco, May 2004
  44. Mian BM, Agartan C, Whitbeck C, Levin R: Development of Novel Superficial Bladder Cancer Model in Rabbit to Facilitate Endoscopic Evaluation of Intravesical and Intralesional Therapies: A Preliminary Report. 100th Annual Meeting, American Urological Association, San Francisco, May 2004 AND 95th Annual Meeting of American Association for cancer Research, Orlando, March 2004
  45. Lehr DJ, Moore CK, Nazeer T, Karikehalli S, Mian BM: Effect of Prostate Sampling Technique on the Correlation between Biopsy and Prostatectomy Gleason Scores in the Contemporary Era. 100th Annual Meeting, American Urological Association, San Francisco, May 2004
  46. Ha XA, Giorgi L, Melendez JA, Mian BM: Oxidative Stress Index Correlates with Tumorigenic Potential in Bladder Cancer Cell Lines. 95th Annual meeting of American Association for cancer Research, Orlando, March 2004
  47. Moore CK, Karikehalli S, Nazeer T, Fisher HA, Kaufman RP, Mian BM: Prognostic value of high-grade prostatic intraepithelial neoplasia and atypia in the extended prostate biopsy era. 99th Annual Meeting, American Urological Association, Chicago, May 2003
  48. Nazeer T, Jennings T, Ross J, Anwar S, Mian B.  Impact of extended biopsy schemes on prostatic adenocarcinoma detection in recent biopsy specimens.   Mod  Pathol 16 (1); 163A: 2003.
  49. Moore C, Anwar S, Nazeer T, Fisher HAG, Kaufman RP, Jr., Mian BM: Detection of prostate cancer in men undergoing repeat prostate biopsy: effect of extended biopsy scheme. Canadian Journal of Urology; 9(4),1619, 2002.
  50. Mian BM, Naya Y, Okihara K, Vakar-Lopez, F, Troncoso P, Babaian RJ: Predictors of cancer in repeat extended multi-site prostate biopsy in men with previous negative extended multi-site biopsy. 98th Annual Meeting, American Urological Association, Orlando, FL, June 2002
  51. Mian BM, Dinney CPN, Sweeney P, Tellez CS, Gudas J, Bar-Eli M: Fully human anti-interleukin-8 antibody inhibits growth of tumor cells implanted into the bladders of athymic of nude mice.  93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  52. Mian BM, Sweeney P, Kedar D, Slaton JW, Huang S, Czerniak B, Ward N, Dinney CPN: Invasive index of non-transitional cell and transitional cell cancers of the bladder: Explanation for aggressive biologic behavior.
  53. 93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  54. Huang S, Mills L, Mian BM, Tellez C, McCarty M, Yang XD, Gudas J, Bar-Eli M: Fully human anti-IL-8 (ABX-IL8) inhibits angiogenesis, tumor growth and metastasis of human melanoma. 93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  55. Kedar DM, Sweeney P, Huang, Mian BM, Dinney CPN, Rosenblum MG: Targeting of bladder cancer vascular endothelium with VEGF121/rGel fusion toxin. 93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  56. Huang SF, Kim SJ, Lee AT, Karashima T, Kedar D, Sweeney JP, Mian BM, Killion J, Fidler IJ: Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with docetaxel and pegylated interferon-a-2b. 93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  57. Karashima T, Kim SJ, Sweeney P, Kamat A, Mian BM, McConkey D, Dinney CPN: The expression of interleukin-8 in human transitional cell carcinoma is regulated by changes in the microenvironment (acidosis and hypoxia) via NFkB. 93rd Annual Meeting, American Association of Cancer Research, San Francisco, April 2002
  58. Mian BM, Troncoso P, Okihara K, Bhadkamkar V, Johsnton D, Babaian RJ: Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. 97th Annual Meeting, American Urological Association, Anaheim, CA, May 2001
  59. Eve B, Mian BM, Dinney CPN: Transfection with VEGF isoform 165 enhances the tumorigenicity of human bladder cancer growing orthotopically in the bladders of athymic nude mice. 97th Annual Meeting, American Urological Association, Anaheim, CA, May 2001
  60. Huang SF, Slaton JW, Karashima T, Mian BM, Sweeney JP, Pettaway CA: Development and characterization of a novel orthotopic model of penile squamous carcinoma in nude mice. 92nd Annual Meeting, American Association of Cancer Research, New Orleans, LA, March 2001
  61. Sweeney JP, Kedar D, Karashima T, Mian BM, Huang SF, Hicklin D, Pettaway CA, Kim SJ, Dinney CPN: Monoclonal VEGF (flk) receptor antibody (DC101) reduces tumorigenicity and cellular proliferation, and enhances apoptosis in orthotopic prostate cancer xenograft in nude mice. 92nd Annual Meeting, American Association of Cancer Research, New Orleans, LA, March 2001
  62. Mian BM, Bhadkamkar N, Slaton JW, Swanson DA, Pisters LL: Sarcomatoid renal cell carcinoma: Effect of multi-modal therapy. South-central section-American Urological Association, Montreal, Canada, August 2000
  63. Despradel VM, Mian BM, Terranova SA, Averch TD: Use of Holmium laser in conjunction with electro-hydraulic lithotripsy in the treatment of bladder calculi. Mid-Atlantic section-American Urological Association, September 2000
  64. Mian BM, Hackler RH, Morgan WR: Pathologic outcome of radical prostatectomy specimens in patients with low Gleason score cancer in only one core prostate biopsy. 95th Annual Meeting, American Urological Association, Dallas, TX, April 1999
  65. Mian BM, Dumont, M, Averch, TD: Urologic complications of Kidney-Pancreas transplants with bladder drainage. Annual meeting, Mid-Atlantic section, American Urological Association, Homestead, VA, May 1997
  66. Mian BM, Whitworth C, Katz PG: Use of Vacuum Constriction Device for erectile dysfunction in spinal cord injured patients. Seventh World Meeting on Impotence, San Francisco, November 1996

Book Chapters:

  1. Aggarwal H,, Mian BM:  Management of Locally Advanced Prostate Cancer. In Leslie SW (ed): Urology Board Review, 4th edition. 2013
  2. Chughtai B, Mian BM:  Management of Locally Advanced Prostate Cancer. In Leslie SW (ed): Urology Board Review: Pearls of Wisdom 4th edition. 2009
  3. Mian BM, Pisters LL: Locally Advanced or Recurrent Prostate Cancer. In Levy D (ed): Urology Pearls of Wisdom. 2001
  4. Mian BM, Morgan, WR: Spermatic Cord Mass. In Gomella, L (ed): 5-Minute Urology Consult. Lippincott Williams & Wilkins, 2000
  5. Mian BM, Morgan, WR: Testis cancer, Adult. In Gomella, L (ed): 5-Minute Urology Consult. Lippincott Williams & Wilkins, 2000

Clinical Trials:

  1. A Randomized, Open-Label, Phase, 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and Rising Serum Prostate Specific Antigen After Primary Therapy.  Dendreon Corporation.
    Principal Investigator
  2. A Phase 3, Randomized active controlled open label multicenter study to evaluate the efficacy and safety of study drug as compared with mitomycin C in the Intravesical treatment of subjects with BCG recurrent or refractory non-muscle invasive bladder cancer. Endo Pharmaceuticals.
    Principal Investigator
  3. Phase IIb, multicenter, randomized, double blind, placebo-controlled trial to assess the safety and efficacy of study medication in delaying the systemic progression of prostate cancer in patients with intermediate to high risk of recurrence with rising prostate specific antigen (PSA) levels after prostatectomy, prostatectomy and radiotherapy, or radiotherapy alone for localized disease. Myriad. Principal Investigator
  4. A study to evaluate a panel of urine markers for use in patients undergoing evaluation for bladder cancer, ONC-BL-02. Oncocyte Corporation.
    Principal Investigator
  5. A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing Transurethral Resection for Non-Muscle Invasive Bladder Cancer. Spectrum Pharmaceutical.
    Principal Investigator
  6. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical XXX as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer. Spectrum Pharmaceutical.
    Principal Investigator
  7. A randomized multicenter two-arm single-dose double-blind placebo-CONtrolled phase 3 study of intravesical Qapzola (apaziquone) as a chemotherapy adjuvant to TaransUrEthral Resection of bladder Tumors in patients with low-to intermediate risk non-muscle invasive bladder cancer (CONQUER). Spectrum Pharmaceutical.
    Principal Investigator
  8. An Open-Label, Multicenter Phase 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects with Non Muscle-Invasive Carcinoma in Situ (CIS) and/or High-Grade Papillary Disease of the Bladder Previously Treated with Bacillus Calmette-Guérin (BCG). Viventia Bio. 
    Principal Investigator
  9. A Phase 3 Randomized, placebo controlled double-blind study of JNJ-56021927 in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone in subjects with chemotherapy-naïve metastatic castration resistant prostate cancer (mCRPC). Aragon Pharmaceuticals.
    Sub-Investigator
  10. A multi-center, randomized, double blind, placebo-controlled, Phase III study of ARN-509 in Men with Non-Metastatic Castration resistant Prostate cancer. Aragon Pharmaceuticals.
    Sub-Investigator
  11. An international phase 3 Randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (ADAPT). Argos.
    Sub-Investigator
  12. A Randomized Double Blind Parallel Placebo-Controlled Phase v4, Multi-center Study to Assess Efficacy and Safety of Vesicare (Solifenacin succinate) to improve urinary continence of subjects after robotic assisted Radical Prostatectomy. Astellas.
    Sub-Investigator
  13. Post Marketing Study Using Prolieve TM For The Treatment of Benign Prostatic Hyperplasia (BPH). Boston Scientific.
    Sub-Investigator
  14. A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH antagonist) or Leuprolide (GnRH agonist). Ferring.  
    Sub-Investigator
  15. Efficacy and Safety of a New Leuprolide Acetate 22.5 mg Depot formulation in the Treatment of Prostate Cancer. GP Pharm SA.
    Sub-Investigator
  16. A prospective, single blind, randomized, phase III study to evaluate the safety and efficacy of fibrin sealant Grifols (FS Grifols) as an Adjunct to hemostasis during soft tissue open surgeries. Grifols.
    Sub-Investigator
  17. A Phase II, open label study of the effect of GTx-758 as secondary hormonal therapy on serum PSA and serum free testosterone levels in men with metastatic castration resistant prostate cancer, maintained on androgen deprivation therapy. GTx.
    Sub-Investigator
  18. A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy. Janssen.
    Sub-Investigator
  19. A Multicenter, Open-Label, Single-arm, Phase 2 Study of Abiraterone Acetate Plus Prednisone in Subjects with Advanced Prostate Cancer Without Radiographic Evidence of Metastatic Disease. Janssen Services, LLC.
    Sub-Investigator
  20. HERO: A multinational phase 3 randomized, open-label, parallel group study to evaluate the safety and efficacy of Relugolix in Men with Advanced Prostate Cancer. Myovant. 
    Sub-Investigator
  21. Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients with Advanced Breast or Prostate Carcinomas with metastases to bone and receiving ongoing therapy with denosumab or zoledrioni acid. OPKO Ireland Global.
    Sub-Investigator
  22. Metastatic renal Cell Cancer Registry. Pfizer.
    Sub-Investigator
  23. A Randomized, Open Label Multicenter, Phase III, 2-Arm Study of Androgen deprivation with Leuprolide +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a rising PSA Following Definitive Local Therapy. Sanofi-aventis US.
    Sub-Investigator
  24. A Randomized, Double-blind phase III study to evaluate adjuvant study drug treatment vs placebo in patients with clear cell RCC and high risk of recurrence. Wilex, AG.
    Sub-Investigator

Research
Funding:

  • Principal Investigator, “Senescence-Associated, Growth-Regulatory Proteins in Prostate Cancer”.
    VA Merit Review, $162,000 PLUS protected time
    4/2006 – 4/2009
    Time Commitment: 25%
  • Co-Investigator, “Redox Control of Bladder Cancer”.
    J. Andre Melendez, P.I.
    Phillip Morris External Research Program, $1,140,606
    8/2005-8/2008
    Time Commitment: 10%
  • Principal Investigator, “Role of Oxidative Stress in Tumorigenicity and Progression Of Bladder Cancer”.
    Young Investigator Research Grant-in-Aid, Northeastern Section, American Urological Association, $20,000
    3/2004-3/2005
  • Principal Investigator, “Development of a Novel Bladder Carcinogenesis Model”. Research Incentive Fund Stratton VA Medical Center, Albany, NY, $20,000
    3/2003-6/2005